In this framework, Cordero-Coma et al. [49] carried out a prospective study to investigate the effects of adalimumab on the serum cytokine profile in patients with steroid-treated recurrent uveitis, unveiling that reduced IL-22 levels were the only cytokine correlated with disease activity, without finding this effect on steroid-treated patients. The gene discussed is IL22; the disease is uveitis.